Holen Sie sich die Stockscreener-App
47.48
0.02%
0.010
Handel nachbörslich:
47.50
0.02
+0.04%
Schlusskurs vom Vortag:
$47.47
Offen:
$46.88
24-Stunden-Volumen:
3.68M
Relative Volume:
0.98
Marktkapitalisierung:
$20.34B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$1.30B
KGV:
27.15
EPS:
1.7487
Netto-Cashflow:
$1.05B
1W Leistung:
+4.58%
1M Leistung:
+10.50%
6M Leistung:
+29.51%
1J Leistung:
+40.22%
1-Tages-Spanne:
$46.44
$47.66
1-Wochen-Bereich:
$44.88
$47.66
52-Wochen-Spanne:
$29.66
$47.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
47.48 | 20.34B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz
Royalty Pharma Appoints Kenneth Sun as Senior VP and Head of Asia - National Today
Affiliated holders sell large RPRX stakes (RPRX) in Feb 2026 trades - Stock Titan
Royalty Pharma Plc (RPRX): Investor Outlook With 11.57% Upside Potential - DirectorsTalk Interviews
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks Q4 Earnings Call Highlights - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com
Royalty Pharma appoints Kenneth Sun to lead Asia expansion By Investing.com - Investing.com Canada
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform - marketscreener.com
Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026 - marketscreener.com
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - The Spec
Citigroup Inc. Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
RPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why - Finviz
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why - Yahoo Finance
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
Cowen Maintains Buy on Royalty Pharma plc (RPRX) Feb 27, 2026 - Meyka
TD Cowen raises Royalty Pharma stock price target to $50 on growth - Investing.com UK
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen - StreetInsider
Royalty Pharma stock hits 52-week high at 46.14 USD - Investing.com
Royalty Pharma PLC $RPRX Shares Sold by Vanguard Group Inc. - MarketBeat
Short Interest in Royalty Pharma PLC (NASDAQ:RPRX) Declines By 49.2% - MarketBeat
(RPRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Royalty Pharma fireside chat webcast from TD Cowen health conference - Stock Titan
Royalty Pharma Plc Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
CFO-linked entities at Royalty Pharma (RPRX) sell 34,791 Class A shares - Stock Titan
JPMorgan Chase & Co. Has $62.08 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Performance Recap: What are Precision Drilling Corporations recent SEC filings showingWeekly Earnings Recap & Growth Focused Entry Point Reports - baoquankhu1.vn
RPRX affiliates file Rule 144 resale notices (NASDAQ: RPRX) - Stock Titan
Royalty Pharma (RPRX) Stock Report: Analysts See a 13% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
Tredje AP fonden Sells 39,546 Shares of Royalty Pharma PLC $RPRX - MarketBeat
HighTower Advisors LLC Raises Stock Position in Royalty Pharma PLC $RPRX - Defense World
Support Test: Is Royalty Pharma plc benefiting from innovation trends2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
RPRX (Royalty Pharma) PB Ratio : 2.99 (As of Feb. 21, 2026) - GuruFocus
Can Royalty Pharma plc stock deliver strong Q4 earningsNew Guidance & Consistent Growth Stock Picks - mfd.ru
PTC’s Sephience Launch Appears Off To A Strong Start - Citeline News & Insights
Will Royalty Pharma plc outperform the market in YEARDay Trade & Safe Capital Allocation Plans - mfd.ru
CenterBook Partners LP Reduces Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Bought by Aberdeen Group plc - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma's Q4 Earnings Call - Finviz
Heartland Advisors Inc. Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call - Barchart.com
Stronger 2026 Guidance, Buybacks, and Manager Shift Might Change The Case For Investing In Royalty Pharma (RPRX) - simplywall.st
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighWhat's Next? - MarketBeat
Royalty Pharma : Q4 2025 Financial Results Call Transcript - marketscreener.com
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.89%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):